437 related articles for article (PubMed ID: 12756828)
1. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
2. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
3. Private sector contributions to pharmaceutical science: thirty-five summary case histories.
Zycher B; DiMasi JA; Milne CP
Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102
[TBL] [Abstract][Full Text] [Related]
4. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
5. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
6. Introducing new contraceptives.
Segal SJ; Coutinho E
Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
[TBL] [Abstract][Full Text] [Related]
7. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
8. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
Wheeler C
Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
[No Abstract] [Full Text] [Related]
9. Drugs firms inflate research costs, watchdog says.
Knight J
Nature; 2001 Aug; 412(6847):571. PubMed ID: 11493879
[No Abstract] [Full Text] [Related]
10. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
11. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
12. [Development of new drugs is too expensive].
Andreasen J
Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
[No Abstract] [Full Text] [Related]
13. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
14. Obstacles and opportunities in new drug development.
Kaitin KI
Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
[No Abstract] [Full Text] [Related]
15. [Openness in the cooperation between physicians and private corporations].
Jørgensen J; Djurhuus JC
Ugeskr Laeger; 2003 Apr; 165(16):1642-5. PubMed ID: 12756817
[TBL] [Abstract][Full Text] [Related]
16. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
17. The AMPPA network as a successful model for public-private or private-private partnership.
Diczfalusy E; Fathalla M; Habenicht UF; Stock G
Mol Cell Endocrinol; 2004 Mar; 216(1-2):1-4. PubMed ID: 15109738
[TBL] [Abstract][Full Text] [Related]
18. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
Hentschel CC
Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
[No Abstract] [Full Text] [Related]
19. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
20. Australia's 'free-ride' in pharmaceuticals: can it last?
Kemp R
Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]